160 related articles for article (PubMed ID: 33793112)
21. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.
He J; Pan Y; Guo Y; Li B; Tang Y
J Immunother; 2020 Jun; 43(5):156-164. PubMed ID: 32168233
[TBL] [Abstract][Full Text] [Related]
22. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
23. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
24. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
Carosio R; Fontana V; Mastracci L; Ferro P; Grillo F; Banelli B; Canessa PA; Dessanti P; Vigani A; Morabito A; Pfeffer U; Poggi A; Roncella S; Pistillo MP
J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
[TBL] [Abstract][Full Text] [Related]
25. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
[No Abstract] [Full Text] [Related]
26. Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma.
Wei H; Wu F; Mao Y; Zhang Y; Leng G; Wang J; Zhang W; Wang T
Jpn J Clin Oncol; 2022 Apr; 52(4):331-345. PubMed ID: 35106596
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.
Wang L; Wang H; Chen H; Wang WD; Chen XQ; Geng QR; Xia ZJ; Lu Y
Oncotarget; 2015 Dec; 6(38):41228-36. PubMed ID: 26515600
[TBL] [Abstract][Full Text] [Related]
28. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
29. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Tiako Meyo M; Jouinot A; Giroux-Leprieur E; Fabre E; Wislez M; Alifano M; Leroy K; Boudou-Rouquette P; Tlemsani C; Khoudour N; Arrondeau J; Thomas-Schoemann A; Blons H; Mansuet-Lupo A; Damotte D; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085544
[TBL] [Abstract][Full Text] [Related]
30. Soluble PD‑L1 reflects cachexia status in patients with gastric cancer and is an independent prognostic marker for relapse‑free survival after radical surgery.
Matsumoto Y; Sasaki T; Kano M; Shiraishi T; Suito H; Murakami K; Toyozumi T; Otsuka R; Kinoshita K; Iida S; Morishita H; Nishioka Y; Hayano K; Kurata Y; Hayashi H; Matsubara H
Mol Clin Oncol; 2023 May; 18(5):39. PubMed ID: 37035474
[TBL] [Abstract][Full Text] [Related]
31. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.
Niu M; Liu Y; Yi M; Jiao D; Wu K
Front Immunol; 2022; 13():827921. PubMed ID: 35386715
[TBL] [Abstract][Full Text] [Related]
32. sPD-L1 and sPD-L2 in plasma of patients with lung cancer and their clinical significance.
Han S; Zhang Y; Yuan J; Wu Y; Zhou Y; Zhou Y; Li X; Zhou S
Cytokine; 2024 Apr; 176():156532. PubMed ID: 38330638
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Significance of Soluble PD-L1 on Cardiovascular Outcomes in Patients with Coronary Artery Disease.
Miyazaki S; Fujisue K; Yamanaga K; Sueta D; Usuku H; Tabata N; Ishii M; Hanatani S; Hoshiyama T; Kanazawa H; Takashio S; Arima Y; Araki S; Yamamoto E; Matsushita K; Tsujita K
J Atheroscler Thromb; 2024 Apr; 31(4):355-367. PubMed ID: 37793811
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
[TBL] [Abstract][Full Text] [Related]
35. Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood.
Keber CU; Derigs M; Schultz C; Wegner M; Lingelbach S; Wischmann V; Hofmann R; Denkert C; Hegele A; Hänze J
Cancer Immunol Immunother; 2022 Oct; 71(10):2381-2389. PubMed ID: 35184226
[TBL] [Abstract][Full Text] [Related]
36. Soluble Programmed Cell Death Ligand-1 (sPD-L1) Levels in Various Cancer Types and Normal Populations.
Lee SH; Park HJ; Moon JY; Kim YT; Lee KR; Kwak MJ; Kim YJ
Clin Lab; 2023 Apr; 69(4):. PubMed ID: 37057933
[TBL] [Abstract][Full Text] [Related]
37. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
Cheng Y; Wang C; Wang Y; Dai L
Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
[TBL] [Abstract][Full Text] [Related]
39. [Novel miRNAs as Potential Regulators of PD-1/PD-L1 Immune Checkpoint, and Prognostic Value of MIR9-1 and MIR124-2 Methylation in Ovarian Cancer].
Kushlinskii NE; Loginov VI; Utkin DO; Filippova EA; Burdennyy AM; Korotkova EA; Pronina IV; Lukina SS; Smirnova AV; Gershtein ES; Braga EA
Mol Biol (Mosk); 2020; 54(6):990-996. PubMed ID: 33276362
[TBL] [Abstract][Full Text] [Related]
40. Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas.
Asanuma K; Nakamura T; Hayashi A; Okamoto T; Iino T; Asanuma Y; Hagi T; Kita K; Nakamura K; Sudo A
Sci Rep; 2020 Jun; 10(1):9077. PubMed ID: 32493964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
